Intensive short‐term chemotherapy regimen induces high remission rate (over 90%) and event‐free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia
Giuseppe Todeschini(University of Pisa), Giovanni Pizzolo(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo Marino(Università Cattolica del Sacro Cuore), Alberto Zamò(University of Verona), Rita Balter(Azienda Ospedaliera Universitaria Integrata Verona), Cristina Tecchio(University of Verona), Massimiliano Bonifacio(University of Verona), Filíppo Gherlinzoni(Ca' Foncello Hospital), Giuseppe Carli(Presidio Ospedaliero), Fausto Adami(University of Padua), Gianpietro Semenzato(University of Padua), Pierluigi Marradi(Azienda Ospedaliera Universitaria Integrata Verona), Piero Maria Stefani(AULSS 2 Marca Trevigiana), Angelo Paolo Dei Tos(University of Padua)
Cited by 32
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k